HRP20120660T1 - Tekuće formulacije lh - Google Patents
Tekuće formulacije lh Download PDFInfo
- Publication number
- HRP20120660T1 HRP20120660T1 HRP20120660AT HRP20120660T HRP20120660T1 HR P20120660 T1 HRP20120660 T1 HR P20120660T1 HR P20120660A T HRP20120660A T HR P20120660AT HR P20120660 T HRP20120660 T HR P20120660T HR P20120660 T1 HRP20120660 T1 HR P20120660T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation according
- luteinizing hormone
- concentration
- formulation
- hlh
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims abstract 29
- 239000000203 mixture Substances 0.000 title claims abstract 29
- 239000007788 liquid Substances 0.000 title 1
- 102000009151 Luteinizing Hormone Human genes 0.000 claims abstract 17
- 108010073521 Luteinizing Hormone Proteins 0.000 claims abstract 17
- 229940040129 luteinizing hormone Drugs 0.000 claims abstract 17
- 239000008363 phosphate buffer Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012669 liquid formulation Substances 0.000 claims abstract 3
- 239000004475 Arginine Substances 0.000 claims abstract 2
- 239000004472 Lysine Substances 0.000 claims abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000000087 stabilizing effect Effects 0.000 claims abstract 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims 5
- 229930182817 methionine Natural products 0.000 claims 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000000022 bacteriostatic agent Substances 0.000 claims 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 3
- 235000019800 disodium phosphate Nutrition 0.000 claims 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- 208000007984 Female Infertility Diseases 0.000 claims 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 2
- 206010021928 Infertility female Diseases 0.000 claims 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 2
- 208000007466 Male Infertility Diseases 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Tekuća formulacija koja sadr·i luteinizirajući hormon (LH) ili njegovu varijantu naznačena time da navedena formulacija sadr·i fosfatni pufer i stabilizirajuću količinu arginina ili njegovih soli u koncentraciji od 10 do 50 mg/ml i/ili lizina ili njegovih soli u koncentraciji od 10 do 50 mg/ml. Patent sadr·i jo® 26 patentnih zahtjeva.
Claims (27)
1. Tekuća formulacija koja sadrži luteinizirajući hormon (LH) ili njegovu varijantu naznačena time da navedena formulacija sadrži fosfatni pufer i stabilizirajuću količinu arginina ili njegovih soli u koncentraciji od 10 do 50 mg/ml i/ili lizina ili njegovih soli u koncentraciji od 10 do 50 mg/ml.
2. Formulacija prema zahtjevu 1, naznačena time da luteinizirajući hormon (LH) je humani luteinizirajući hormon (hLH).
3. Formulacija prema zahtjevu 1 ili 2, naznačena time da luteinizirajući hormon (LH) je rekombinantni humani luteinizirajući hormon (r-hLH).
4. Formulacija prema zahtjevu 1 ili 2, naznačena time da luteinizirajući hormon (LH) je urinarni humani luteinizirajući hormon (u-hLH).
5. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da je luteinizirajući hormon (LH) prisutan u koncentraciji od oko 1 do od oko 50 μg/ml.
6. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da fosfatni pufer je prisutan u koncentraciji od 1 do100 mM.
7. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da je fosfatni pufer poželjno natrijev fosfatni pufer.
8. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da nadalje sadrži surfaktant.
9. Formulacija prema zahtjevu 8, naznačena time da surfaktant je Polisorbat 20.
10. Formulacija prema zahtjevu 9, naznačena time da je Polisorbat 20 prisutan u koncentraciji od 0,01 do 10 mg/ml.
11. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da nadalje sadrži metionin.
12. Formulacija prema zahtjevu 11, naznačena time da je metionin prisutan u koncentraciji od 0,01 do 5,0 mg/ml.
13. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da nadalje sadrži bakteriostatsko sredstvo.
14. Formulacija prema zahtjevu 13 naznačena time da je bakteriostatsko sredstvo odabrano od bilo kojeg od benzil alkohola, fenola i kombinacije benzil alkohola i benzalkonijevog klorida.
15. Formulacija prema zahtjevu 13 ili 14, naznačena time da je bakteriostatsko sredstvo prisutno u koncentraciji od 0,005 do 15 mg/ml.
16. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da nadalje sadrži vodu za injekcije.
17. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da ima pH u rasponu od 7,5 do 8,5.
18. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da sadrži najmanje 25 μg/ml r-hLH, 1.65 mg/ml Na2HPO4 2H2O, 0.104 mg/ml NaH2PO4 H2O, 31.5 mg/ml L-arginin monohidroklorida, 0,05 mg/ml Tween 20, 0,5 mg/ml metionina i 5 mg/ml fenola.
19. Formulacija prema bilo kojem od zahtjeva 1 do 17 naznačena time da sadrži najmanje 25 μg/ml r-hLH, 1,65 mg/ml Na2HPO4 2H2O, 0,104 mg/ml NaH2PO4 H2O, 28,5 mg/ml lizin monohidroklorida. 0,05 mg/ml Tween 20, 0,5 mg/ml metionina i 12 mg/ml benzil alkohola.
20. Formulacija prema bilo kojem od zahtjeva 1 do 17 naznačena time da sadrži najmanje 25 μg/ml r-hLH. 1,65 mg/ml Na2HPO4 2H2O, 0,104 mg/ml NaH2PO4 H2O, 28,5 mg/ml lizin monohidroklorida, 0,05 mg/ml Tween 20, 0,5 mg/ml metionina, 3 mg/ml benzil alkohola i 0,01 mg/ml i benzalkonijevog klorida.
21. Farmaceutski pripravak naznačen time da sadrži formulaciju prema bilo kojem od zahtjeva 1 do 20.
22. Prezentacijski oblik formulacije prema bilo kojem od zahtjeva 1 do 20 naznačen time da je hermetički zatvoren pod sterilnim uvjetima u spremniku koji je pogodan za pohranjivanje prije uporabe.
23. Postupak za dobivanje formulacije prema bilo kojem od zahtjeva 1 do 20 naznačen time da sadrži razrjeđivanje luteinizirajućeg hormona (LH) sa otopinom koja sadrži pomoćne tvari.
24. Uporaba formulacije prema bilo kojem od zahtjeva 1 do 20 naznačena time da je za dobivanje lijeka.
25. Uporaba formulacije prema bilo kojem od zahtjeva 1 do 20 naznačena time da je za dobivanje lijeka za liječenje neplodnosti žena i/ili muškaraca.
26. Uporaba formulacije prema bilo kojem od zahtjeva 1 do 20 naznačena time da je u kombinaciji sa tekućom formulacijom koja sadrži folikulo-stimulirajući hormon (FSH) ili njegovu varijantu.
27. Formulacija prema bilo kojem od zahtjeva 1 do 20 naznačena time da je za liječenje neplodnosti žena i/ili muškaraca.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07119832 | 2007-11-01 | ||
| US448107P | 2007-11-28 | 2007-11-28 | |
| PCT/EP2008/064679 WO2009056569A1 (en) | 2007-11-01 | 2008-10-29 | Lh liquid formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120660T1 true HRP20120660T1 (hr) | 2012-09-30 |
Family
ID=39167502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120660AT HRP20120660T1 (hr) | 2007-11-01 | 2012-08-15 | Tekuće formulacije lh |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8664369B2 (hr) |
| EP (1) | EP2219607B1 (hr) |
| JP (1) | JP5551601B2 (hr) |
| KR (1) | KR101513181B1 (hr) |
| CN (1) | CN101842083B (hr) |
| AU (1) | AU2008320844B2 (hr) |
| BR (1) | BRPI0818324B8 (hr) |
| CA (1) | CA2700662C (hr) |
| CY (1) | CY1113121T1 (hr) |
| DK (1) | DK2219607T3 (hr) |
| EA (1) | EA019432B1 (hr) |
| EC (1) | ECSP10010224A (hr) |
| ES (1) | ES2393233T3 (hr) |
| HK (1) | HK1145443A1 (hr) |
| HR (1) | HRP20120660T1 (hr) |
| IL (1) | IL205105A (hr) |
| MX (1) | MX2010004639A (hr) |
| MY (1) | MY153976A (hr) |
| NZ (1) | NZ583991A (hr) |
| PL (1) | PL2219607T3 (hr) |
| PT (1) | PT2219607E (hr) |
| RS (1) | RS52566B (hr) |
| SI (1) | SI2219607T1 (hr) |
| UA (1) | UA101484C2 (hr) |
| WO (1) | WO2009056569A1 (hr) |
| ZA (1) | ZA201001907B (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2229407B1 (de) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
| HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| JP2011001273A (ja) * | 2009-06-16 | 2011-01-06 | Eci Inc | ｅＭＩＰを有効成分とする水溶性製剤 |
| JP5735960B2 (ja) * | 2009-07-06 | 2015-06-17 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | メチオニンを含むインスリン製剤 |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| WO2011058082A1 (de) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin |
| WO2011099036A2 (en) * | 2010-02-12 | 2011-08-18 | Intas Biopharmaceuticals Limited | Liquid formulation of follicle stimulating hormone |
| ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN102293756A (zh) * | 2011-08-24 | 2011-12-28 | 蚌埠丰原涂山制药有限公司 | 一种尿促性素冻干粉针剂及其制备方法 |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| WO2014102623A1 (en) * | 2012-12-26 | 2014-07-03 | Wockhardt Limited | Pharmaceutical composition |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN105899190B (zh) | 2014-01-09 | 2022-06-14 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
| AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| SG11201604708VA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| PL3229828T3 (pl) | 2014-12-12 | 2023-07-31 | Sanofi-Aventis Deutschland Gmbh | Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| US5681302A (en) * | 1994-06-14 | 1997-10-28 | Minnesota Mining And Manufacturing Company | Elastic sheet-like composite |
| AU707796B2 (en) * | 1995-03-21 | 1999-07-22 | Merck Serono Sa | HCG liquid formulations |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| IL140984A0 (en) * | 1998-07-23 | 2002-02-10 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
| EP2174663A1 (en) * | 2003-01-08 | 2010-04-14 | Novartis Vaccines and Diagnostics, Inc. | Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant |
| US7387998B2 (en) | 2003-03-28 | 2008-06-17 | New York University | STQ peptides |
| CA2518903C (en) * | 2003-04-02 | 2013-02-05 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
-
2008
- 2008-10-29 PL PL08844750T patent/PL2219607T3/pl unknown
- 2008-10-29 SI SI200830735T patent/SI2219607T1/sl unknown
- 2008-10-29 JP JP2010531519A patent/JP5551601B2/ja active Active
- 2008-10-29 US US12/681,688 patent/US8664369B2/en active Active
- 2008-10-29 BR BRPI0818324A patent/BRPI0818324B8/pt active IP Right Grant
- 2008-10-29 DK DK08844750.3T patent/DK2219607T3/da active
- 2008-10-29 CA CA2700662A patent/CA2700662C/en not_active Expired - Fee Related
- 2008-10-29 KR KR1020107012131A patent/KR101513181B1/ko active IP Right Grant
- 2008-10-29 RS RS20120484A patent/RS52566B/en unknown
- 2008-10-29 WO PCT/EP2008/064679 patent/WO2009056569A1/en active Application Filing
- 2008-10-29 NZ NZ583991A patent/NZ583991A/en unknown
- 2008-10-29 MX MX2010004639A patent/MX2010004639A/es active IP Right Grant
- 2008-10-29 CN CN2008801145250A patent/CN101842083B/zh active Active
- 2008-10-29 PT PT08844750T patent/PT2219607E/pt unknown
- 2008-10-29 MY MYPI2010001950A patent/MY153976A/en unknown
- 2008-10-29 ES ES08844750T patent/ES2393233T3/es active Active
- 2008-10-29 EA EA201070549A patent/EA019432B1/ru not_active IP Right Cessation
- 2008-10-29 UA UAA201006712A patent/UA101484C2/ru unknown
- 2008-10-29 AU AU2008320844A patent/AU2008320844B2/en active Active
- 2008-10-29 EP EP08844750A patent/EP2219607B1/en active Active
-
2010
- 2010-03-17 ZA ZA2010/01907A patent/ZA201001907B/en unknown
- 2010-04-15 IL IL205105A patent/IL205105A/en active IP Right Grant
- 2010-05-31 EC EC2010010224A patent/ECSP10010224A/es unknown
- 2010-12-20 HK HK10111880.8A patent/HK1145443A1/xx unknown
-
2012
- 2012-08-15 HR HRP20120660AT patent/HRP20120660T1/hr unknown
- 2012-09-13 CY CY20121100836T patent/CY1113121T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120660T1 (hr) | Tekuće formulacije lh | |
| JP2011502968A5 (hr) | ||
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| HRP20210298T1 (hr) | Dostava terapijskih agensa u središnji živčani sustav | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| RU2407514C2 (ru) | Водные композиции чфсг | |
| HRP20191843T1 (hr) | Mikobakterijski antigenski pripravak | |
| US11162500B2 (en) | Stable liquid formulation of AMG 416 (etelcalcetide) | |
| TW201630622A (zh) | 速效胰島素組合物 | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| HRP20110444T1 (hr) | Formulacije paratiroidnih hormona i njihove uporabe | |
| EA201492021A1 (ru) | Антительный состав | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| JP2015527402A5 (hr) | ||
| ES2893121T3 (es) | Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación | |
| CN102821782B (zh) | 促卵泡激素的液体配制品 | |
| RU2015115127A (ru) | Жидкие лекарственные композиции апиксабана | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| US20170189528A1 (en) | Stable aqueous adalimumab formulation | |
| HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| HRP20200196T1 (hr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
| HRP20201161T1 (hr) | Formulacije sa smanjenom oksidacijom | |
| BG106512A (bg) | Циклесонид-съдържащ фармацевтичен състав за прилагане върху мукоза |